Eosinophilic Esophagitis Market to Showcase Strong Growth Prospects Rising at a CAGR of 25.5% during the Study Period [2019-2032], Predicts DelveInsight

DelveInsight's "Eosinophilic Esophagitis Market" report provides a thorough comprehension of the Eosinophilic Esophagitis, historical and forecasted epidemiology, and the Eosinophilic Esophagitis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Eosinophilic Esophagitis market report also proffers an analysis of the current Eosinophilic Esophagitis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Eosinophilic Esophagitis: An Overview

Eosinophilic Esophagitis (EoE) represents a chronic, local immune-mediated oesophagal disease, characterized clinically by symptoms related to oesophagal dysfunction and histologically by eosinophil-predominant inflammation. As per the estimates by DelveInsight, the total diagnosed Eosinophilic Esophagitis prevalent cases in 2020 were 547,924 cases. The highest prevalent cases were observed in the United States, accounting for approximately 58% of the total cases.

Download Sample Report @ https://www.delveinsight.com/sample-request/eosinophilic-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key highlights of the Eosinophilic Esophagitis Market Report
The US FDA has granted priority review, breakthrough therapy designation, and orphan designation to Budesonide Oral Suspension (BOS) for the EoE treatment.

In the Phase II study, RPC4046 demonstrated positive results. Currently, Bristol-Myers Squibb is conducting a Phase III clinical study to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with the indication.
APT-1011 has received orphan drug designation from the FDA. It is currently in Phase III development (FLUTE II), following the successful completion of its phase II study (FLUTE I) in 2019.
Benralizumab is currently approved under the brand name Fasenra as an add-on maintenance treatment of severe asthma in patients aged ≥12 years and with an eosinophilic phenotype. Now, it is being evaluated in the Phase III study for the treatment of EoE.

The Eosinophilic Esophagitis Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Diagnosed Eosinophilic Esophagitis Prevalence
Gender-specific Eosinophilic Esophagitis Cases
Age-specific Eosinophilic Esophagitis Cases

Get a sample copy of this market report @ https://www.delveinsight.com/sample-request/eosinophilic-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Eosinophilic Esophagitis Treatment Market

The Eosinophilic Esophagitis treatment involves Drugs, Diet, and Dilation. The first two components, which involve the use of proton pump inhibitors (PPIs), corticosteroids, immunosuppressants, and empirical diets or guided food elimination based on allergy tests, are more useful in the initial phases. In contrast, endoscopic dilation is reserved for oesophagal strictures.

Three dietary approaches for the management of EoE have emerged: the elemental diet, empiric dietary restrictions, and targeted dietary restrictions based on allergy testing.
PPIs are helpful as a first-line treatment for EoE patients. This therapy reduces acid production in the stomach and can reduce oesophagal inflammation. PPIs are recommended to be administered twice daily and continued for a minimum 2-month course after oesophagal eosinophilia is discovered. Afterwards, a repeat endoscopy with biopsies is performed to assess for persistent eosinophilic infiltration.

Corticosteroids, which control inflammation, are another effective therapy for the treatment of EoE. By swallowing small doses of corticosteroids, they contact and treat the inner lining of the oesophagus. Different forms of swallowed corticosteroids are available. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission.
Oesophagal endoscopic dilation is most commonly used in adults with established oesophagal strictures. Although many physicians are fearful of dilating Eosinophilic Esophagitis patients due to concerns regarding mucosal tears and perforations, numerous case series attest to the safety and efficacy of oesophagal dilation.
The Food and Drug Administration currently approves no drugs for the EoE treatment. However, off-label medications have also been shown to reduce the number of eosinophils in the oesophagus and improve symptoms.

Eosinophilic Esophagitis Emerging Therapies Along with Key Players
Budesonide Oral Suspension: Takeda
Dupilumab: Regeneron Pharmaceuticals/Sanofi
Cendakimab: Bristol-Myers Squibb
APT-1011: Ellodi Pharmaceuticals
Benralizumab: AstraZeneca
Lirentelimab: Allakos, and Several Others

Browse More Related Reports @ https://www.delveinsight.com/report-store/eosinophilic-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Eosinophilic Esophagitis Market Drivers and Market Barriers
Eosinophilic Esophagitis Market Drivers such as increasing awareness, the emergence of non-invasive modalities, identification of biomarkers, and the development of animal models are responsible for Market Growth. In contrast, Eosinophilic Esophagitis Market Barriers such as high cost of treatment, lack of multidisciplinary management, and lack of optimal endpoint for treatment will nosedive the market size.

Table of Content
1. Key Insights
2. Executive Summary of Eosinophilic Disorder
3. Competitive Intelligence Analysis for Eosinophilic Disorder
4. Eosinophilic Disorder: Market Overview at a Glance
5. Eosinophilic Disorder: Disease Background and Overview
6. Patient Journey
7. Eosinophilic Disorder Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Eosinophilic Disorder Unmet Needs
10. Key Endpoints of Eosinophilic Disorder Treatment
11. Eosinophilic Disorder Marketed Products
13. Eosinophilic Disorder: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Eosinophilic Disorder
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in touch with our business expert @ https://www.delveinsight.com/report-store/eosinophilic-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.